Teva Pharmaceutical Industries (NYSE:TEVA) is a global leader in generic and specialty medicines, offering a broad portfolio of products that treat a wide range of conditions. The company’s generic division produces cost-effective versions of branded pharmaceuticals, enabling health systems and patients to access essential treatments at more affordable prices. In parallel, Teva’s specialty medicines arm focuses on innovative therapies in areas such as central nervous system (CNS) disorders, respiratory diseases and pain management.
Founded in Jerusalem in 1901, Teva has grown through organic development and strategic acquisitions to become one of the world’s largest pharmaceutical companies. Key milestones include the merger with Ivax Corporation in 2006 and the acquisition of Allergan’s generic business in 2016, which significantly expanded Teva’s product range and manufacturing footprint. These initiatives have reinforced the company’s ability to bring both generics and novel medicines to market efficiently.
Teva’s product lineup encompasses thousands of molecules, including widely prescribed generic drugs and proprietary specialty treatments such as Copaxone for multiple sclerosis, Austedo for chorea associated with Huntington’s disease, and Ajovy for migraine prevention. In addition to finished dosage forms, Teva operates a robust active pharmaceutical ingredient (API) business, supplying key intermediates and finished APIs to partners around the world.
Headquartered in Petah Tikva, Israel, Teva serves patients in more than 60 countries and employs a global workforce of over 30,000. Under the leadership of CEO Kåre Schultz, the company continues to pursue cost leadership, operational excellence and a strong R&D pipeline. Through its commitment to accessibility and innovation, Teva aims to deliver high-quality medicines that address unmet medical needs and support sustainable healthcare systems worldwide.
